SCHEMBL842032

SCHEMBL842032

CC(N)c1cccc(-c2ccc(NS(C)(=O)=O)cc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 1/20 0.50
HSD17B2 P37059 1/20 0.50
KIF11 P52732 5/20 0.49
KDM1A O60341 1/20 0.48
PIP4K2A P48426 1/20 0.47
PIP4K2B P78356 1/20 0.47
CDC7 O00311 1/20 0.46
PLK4 O00444 1/20 0.46
DAPK3 O43293 1/20 0.46
DYRK3 O43781 1/20 0.46
JAK2 O60674 1/20 0.46
ROCK2 O75116 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
CDK1 P06493 1/20 0.46
ROS1 P08922 1/20 0.46
CDK2 P24941 1/20 0.46
MARK3 P27448 1/20 0.46
TYK2 P29597 1/20 0.46
KDR P35968 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL860476 1.00 HSD17B1 (0.50) HSD17B1HSD17B2KIF11KDM1APIP4K2A
SCHEMBL13524607 0.88 RXRA (0.53) HSD17B1HSD17B2KIF11KDM1APIP4K2A
SCHEMBL4370199 0.84 KEAP1 (0.52) HSD17B1HSD17B2KIF11KDM1AEGFR
SCHEMBL18427042 0.79 KEAP1 (0.64) HSD17B1HSD17B2KIF11KDM1APIP4K2A
SCHEMBL2002046 0.79 CA12 (0.55) KIF11KEAP1
SCHEMBL4442941 0.79 CA12 (0.55) KIF11KEAP1
Hydrochloric Acid SCHEMBL1285481 0.77 LMNA (0.55) KIF11KEAP1
SCHEMBL13524566 0.77 KIF11 (0.56) HSD17B1HSD17B2KIF11KDM1AJAK2
SCHEMBL5426884 0.76 HSD17B1 (0.56) HSD17B1HSD17B2KIF11KDM1APIP4K2A
SCHEMBL21180002 0.76 KIF11 (0.62) HSD17B1HSD17B2KIF11KDM1APIP4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176223-B1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI SA (FR) 2013-01-23 EP disclosed
US-8143242-B2 Malonamide derivatives with antithrombotic activity SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2010-09-30 US disclosed
EP-2176223-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY Sanofi-Aventis (FR) 2010-04-21 EP disclosed
WO-2009007015-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY F7, F9, TFPI HSD17B1 1802/4885HSD17B2 2178/4885KIF11 3928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.